Introduction
and monocyte chemoattractant protein-1 (MCP-1)/CCL2 and other chemokines essential 75 to the recruitment of inflammatory cells to infection sites (18, 19) . 76
77
The T cruzi outer membrane parasite-derived neurotrophic factor (PDNF) and a short-78 form that contains receptor-binding sites (sPDNF) (20, 21) binds and activates nerve 79 growth factor (NGF) receptor TrkA (22) and neurotrophin-3 (NT-3) receptor TrkC (23), 80 triggering host-cell survival events and parasite host-cell entry (24, 25) . PDNF was 81 identified in 1983 in our lab as neuraminidase (26) consequent to the discovery of sialic 82 acid in T cruzi (27, 28) . Nine years after its discovery, the neuraminidase was found to 83 catalyze the covalent transfer sialyl residues to β-Gal acceptors from glycoconjugates, 84 hence its re-naming trans-sialidase (29, 30) , even though the molecule has both 85 neuraminidase and trans-sialidase activities (31). However, neurotrophic receptor 86 activation is independent of sialic acid binding because the neuraminidase/trans-87 sialidase 1) does not lose Trk receptor recognition after point mutations that sharply 88 reduce neuraminidase/trans-sialidase activities (32), 2) Trk-binding activity is mimicked 89 by a 24-mer synthetic peptide (33), and 3) binds and activates Trk receptors in sialic 90 acid-deficient cells (25) . Furthermore, the enzyme, after phosporylation by Akt kinase, 91 promotes cell survival in the cytosol where sialyl-conjugate substrates are absent (34) . 92
Neuraminidase/trans-sialidase is called PDNF to underscore paracrine growth factor 93 function independent of sialic acid binding. Binding to TrkC leads to T cruzi entry into 94 cardiomyocytes and cardiac fibroblasts, whereas binding to TrkA triggers 95 cardioprotection by autocrine and paracrine mechanisms (35, 36) . 96 97 Four years ago it was reported that connective tissue growth factor (CTGF), also known 98 as CCN2, a matricellular protein implicated in fibrosis and inflammation in several 99 disorders such as diabetic neuropathy (37), augments expression of various proto grow T cruzi) in DMEM/1% FCS. Cells were incubated at 37°C in a humidified 126 atmosphere containing 5% CO 2 . 127
(ii) Primary cardiomyocytes and cardiac fibroblasts. Cells were isolated using a 128 modified version of a previously described procedure (35, 36, 41) . In short, neonatal 129 C56BL/6 mice (1-3 days old) were sacrificed by decapitation, their hearts excised and 130 washed twice in PBS, then kept in 20 mM HEPES, 130 mM NaCl, 1mM NaH 2 PO 4 , 4 mM 131 glucose, 3 mM KCl, pH 7.6 for 10 minutes on ice. Hearts were minced and digested in 132 0.25% Trypsin-EDTA (Gibco) 3-4 times at 37°C with periodic mixing. Dissociated cells 133
were pooled and digestion stopped with DMEM/10% FCS, filtered through a 100 μm cell 134 strainer, centrifuged at 500 x g, and plated for 3 h on 1% gelatin-coated plates in DMEM 135 (Gibco)/F12 Ham's (Sigma) 50:50, 20% FCS (PAA), 5% horse serum (PAA), 2 mM L-136 glutamine (Gibco), 0.1 mM nonessential amino acids (Gibco), 3 mM sodium pyruvate 137 (Gibco), and 1 μg/ml bovine insulin (Sigma) with 1x penicillin-streptomycin (Gibco). Non-138 adherent cells (cardiomyocytes) were remove and plated onto new gelatin-coated plates 139 while adherent cells (cardiac fibroblasts) remained in the initial plate in DMEM/10% FCS 140 until needed. Cardiomyocytes contained <5% cardiac fibroblasts and vice versa for 141 cardiac fibroblasts, as determined by immunofluorescence using antibodies against the 142 cardiomyocyte marker myosin heavy chain (MHC) and cardiac fibroblast marker 143 vimentin, as described earlier (35) . 144 145 Purification of recombinant sPDNF: PDNF was cloned from the T cruzi Silvio X-10/4 146 strain (GenBank accession number AJ002174), and a N-terminal short-form of PDNF 147 (sPDNF) that contains Trk-binding sites, was expressed in BL21 (DE3) bacteria, and 148 purified by Ni-affinity chromatography, as described previously (22, 24, 25, 35 to DMEM/5% FCS and cells were infected with T cruzi at an MOI (multiplicity of 160 infection) of 10 for 10-24 h, at which time parasites were washed off. At 3, 24, and 72 h 161 post-infection (PI), cell monolayers were collected in Trizol reagent (Invitrogen) to isolate 162 RNA to generate cDNA for qPCR. 163
(ii) sPDNF. Primary cardiomyocytes and cardiac fibroblasts, and H9c2 cardiomyocytes 164 were seeded at 6-8 x 10 4 cells per well in DMEM/10% FCS and allowed to adhere 165 overnight, serum starved (DMEM/0.1% FCS overnight), and treated with sPDNF (0.5 166 ng/ml -8 μg/ml, 0-16 h). Cell supernatants were collected and stored at - and sacrificed at various days post-infection (DPI) by CO 2 asphyxiation and cervical 223 dislocation. Organs were perfused by intracardiac injection of 5 ml ice-cold PBS, and the 224 heart (sometimes, atria and ventricle were collected separately) and other organs were 225 collected and flash frozen in liquid nitrogen and stored at -80°C. Tissue parasitism was 226 quantified using a qPCR method previously described (24, 25, 42) . 227
(ii) IV administration. sPDNF was diluted in sterile endotoxin-free PBS in 200 μl and 228 injected via the tail vein into 6-8 week old female C57BL/6 mice. Mice receiving single IV 229 injections of 150 μg sPDNF per mouse were sacrificed at 3, 6, 9, and 12 h post-injection, 230 or various doses of sPDNF (100 ng-150 μg) and sacrificed 3-h post-injection. Mice 231 receiving multiple injections of sPDNF or PBS vehicle control (0, 3, and 24 h, 100 μg per 232 injection) were sacrificed 24 h after the last injection (i.e., 48 h after the first injection. 233
Mice were perfused with PBS and organs harvested as described above in ( extending an earlier study (43), we found that T cruzi infection of primary 247 cardiomyocytes and cardiac fibroblasts upregulate MCP-1 and FKN transcripts in a time-248 dependent manner ( Fig. 1a and b ). In addition, the stimulatory activity of T cruzi is 249 mimicked by sPDNF, as it stimulates an increase in MCP-1 and FKN transcripts in both 250 primary cardiomyocytes and cardiac fibroblasts in a dose-dependent manner ( Fig. 1c  251 
and d). 252
In the cardiomyocyte cell line H9c2, sPDNF dramatically increased secretion of MCP-1 253 dose-dependently ( Fig. 2a) and specifically, as sPDNF does not alter secretion of 254 another chemokine, macrophage inflammatory protein-2α/MIP-2α/CXCL2, or the 255 cytokine IL-6 (Fig. 2a) . Similar to the results obtained with primary cardiomyocytes, the 256 increase in MCP-1 and FKN mRNA in H9c2 cardiomyocytes is dose-dependent (Fig 2  257 b). Furthermore, time-course analysis reveals that MCP-1 and FKN transcripts increase 258 maximally 3-h after sPDNF stimulation and drops sharply to levels similar to 259 unstimulated cells after 8-h, in a typical pulse-like kinetics (Fig. 2c, d) . We found that antibodies against TrkA (α-TrkA + sPDNF) significantly block sPDNF-294 induced upregulation (+ sPDNF) of MCP-1 (29.2 ± 3.5 % inhibition) and FKN (29.5 ± 5.3 295 % inhibition), as do antibodies against TrkC (MCP-1 inhibition, 53 ± 2.3 %; FKN 296 inhibition, 47.5 ± 1.3 %) (Fig. 3d, e) . In contrast, neutralizing antibodies against TrkB (α-297 TrkB + sPDNF) are ineffective in preventing sPDNF upregulation of both MCP-1 and 298 FKN (Fig. 3d, e) , consistent with our earlier finding that TrkB is not recognized by 299 sPDNF, thus serving as a negative control for the α-TrkA and α-TrkC inhibition 300 experiments (22, 23). Of note, Trk antibodies, under the conditions used here, have no 301 demonstrable effect on MCP-1 and FKN upregulation (Fig. 3d, e) . In addition, the 302 conclusion sPDNF uses TrkA and TrkC to augment chemokine expression is yet further 303 validated by pre-incubating cardiomyocytes with a mixture of α-TrkA and α-TrkC 304 antibodies, as the results show that the mixture has an additive/synergistic effect in 305 reducing secretion of MCP-1 protein compared to either α-TrkA or α-TrkC alone (Fig.  306   3f) . burden by qPCR (24, 25, 35, 36, 42) . In line with a previous study (45), our results show 323 that levels of MCP-1 and FKN mRNA parallel the degree of heart parasite burden ( heart dose-dependently and with a pulse-like kinetics in both naïve wild type and 331
MyD88
-/-mice. 332
333
The robust MCP-1 increase in acutely infected hearts (Fig. 4a) FKN in the heart of uninfected, naïve mice. A previous pharmacokinetics study showed 341 that sPDNF administered IV into naïve mice has a half-life of ~15 min in the blood and 342 peaks in the myocardium ~15 min post-injection, triggering cardiac responses such as 343
NGF upregulation hours after injection (35). 344 345
We injected groups of naïve wild type C57BL/6 mice with vehicle (PBS) or a single dose 346 of IV sPDNF, sacrificed the mice at various timepoints post-injection, and measured 347 heart MCP-1 and FKN by real time PCR. We found that IV sPDNF significantly 348 upregulates both cardiac MCP-1 and FKN transcripts with pulse-like kinetics, as both 349 chemokines peak shortly after administration (3-h post-injection) and go down quickly to 350 on October 16, 2017 by guest http://iai.asm.org/ Downloaded from levels of un-injected mice (Fig. 5a ). We then screened the agonist effect of IV sPDNF in 351 various organs using optimum time response (3-h post-injection) using the same dose 352 as in Fig. 5a . We found that sPDNF upregulated MCP-1 not only in the heart, liver 353 (where the response was most robust) and spleen, but not in the bone marrow, aorta, 354 esophagus, colon and skin (Fig. 5b) IV sPDNF-triggered MCP-1 and FKN upregulation is dose-dependent in the heart (Fig.  359 5c) and liver ( Fig. 5d ), in agreement with the hypothesis that sPDNF stimulates MCP-1 360 and FKN through a receptor (TrkA and TrkC)-mediated process, akin to the results 361 obtained with cardiac cells in culture (Fig. 3) . 362 363 Although our sPDNF preparations do not have detectable levels of endotoxin (as 364 assessed by the Limulus amebocyte assay), and are non-toxic in recombinase-activating 365 gene-2 (RAG-2 -/-)-deficient mice (data not shown), which are highly susceptible to 366 endotoxin shock (49), we sought to further ensure that the response observed in wild 367 type mice was not due to TLR activation by assessing MCP-1 and FKN response to IV 368 sPDNF in TLR signaling-deficient MyD88 -/-mice (50). Accordingly, our results show that 369 IV sPDNF gives rise to a sharp increase in the expression of both MCP-1 and FKN in the 370 heart and liver of MyD88 -/-mice ( Fig. 5e-h ), further supporting the concept that sPDNF 371 acts on Trks independent of MyD88 signaling. 372 373
Multiple doses, but not a single dose, of IV sPDNF increases expression of MCP-1 374
and FKN receptors CCR2 and CX3CR1 in the mouse heart and liver. 375
One of the functions of MCP-1 and FKN is to attract cells expressing their receptors 377 (CCR2 and CX3CR1, respectively) to tissue sites. We found that CCR2 and CX3CR1 378 transcripts do not increase in cardiac and hepatic tissues following a single IV sPDNF 379 dose ( Fig. 6a and b) , consistent with the finding that MCP-1 and FKN increase is 380 transient and pulse-like (Fig. 5a) . However, sustained tissue exposure to sPDNF 381 obtained by multiple and closely spaced systemic sPDNF injections into naïve mice (IV 382 sPDNF at times 0, 3 and 24 h, measuring chemokines 24 h after the last injection), 383 resulted in a significant increase in CCR2 and CX3CR1 in the liver and heart (ventricle 384 and atrium) ( Fig. 6c and d) . (Figs. 1-3) , acutely infected hearts (Fig. 4b)  441 or in the myocardium following IV sPDNF (Fig. 5) (Fig. 4) . heart with a pulse-like response. Groups of mice (2 per group) were injected with vehicle 553 (Veh) or sPDNF (150 μg/mouse) and sacrificed at 3, 6, 9 and 12 h post-injection, and 554 cardiac MCP-1 and FKN transcripts were quantified by qPCR. Points represent fold 555 change of the mean ± SD relative to Veh-injected mice; *P < 0.05 and **P < 0.01. experiments. The increase in hepatic FKN mRNA was not statistically significant; *** P < 565 0.005. 566
(e-h) TLR signaling-deficient MyD88 -/-mice: 567
MyD88
-/-mice (two per group) were injected IV with vehicle (PBS) or sPDNF (100 μg per 568 mouse), sacrificed 3 h post-injection, and MCP-1 mRNA was quantified in the heart (e) 569 and liver (g) by qPCR, as was FKN mRNA (f and h, respectively). 570 
